New Blood Cell-Based Test Shows Promise in Diagnosing Chronic Fatigue Syndrome
Scientists from the University of Oxford have developed a new blood cell-based test that shows promise in diagnosing chronic fatigue syndrome (CFS), according to a study published in Advanced Science. CFS is a complex disorder characterized by extreme fatigue that cannot be explained by any underlying medical condition. The condition affects millions of people worldwide, yet many struggle to receive a formal diagnosis and appropriate treatment options.
The new test, which analyzes peripheral blood mononuclear cells (PBMCs) using a technique called Raman spectroscopy and an artificial intelligence (AI) tool, has demonstrated an impressive 91 percent accuracy in distinguishing between unaffected individuals and those with CFS. This early diagnosis can help patients manage their condition more effectively and potentially lead to new discoveries in disease pathways and treatment development.
Previous studies have shown that PBMCs from individuals with CFS have reduced energetic function, supporting the theory that the condition is linked to impaired energy production. Building upon this knowledge, the scientists developed the diagnostic approach and tested it in nearly 100 individuals, including those with CFS, healthy controls, and individuals with multiple sclerosis (MS).
The results were promising, with the blood test accurately classifying 91 percent of patients. Furthermore, it could differentiate between mild, moderate, and severe CFS cases with 84 percent accuracy. These findings offer hope for improved patient care and a greater understanding of CFS.
However, more studies are required to validate these findings in larger cohorts, and the method is not currently available in certified diagnostic laboratories. While similar blood cell-based tests using different analytical techniques have shown promise before, progress has been limited.
Nevertheless, this new blood cell-based test is a significant step forward in the field of CFS diagnosis. With further research and development, it has the potential to revolutionize the way this condition is diagnosed and ultimately improve the lives of those affected by CFS.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”